Summary

The Global Veterinary Intravenous (IV) Solutions Market is valued approximately at USD 0.75 billion in 2023 and is anticipated to expand at a compound annual growth rate of 8.37% during the forecast period from 2024 to 2032. Veterinary IV solutions have emerged as a critical cornerstone in modern animal health management, enabling rapid rehydration, fluid therapy, and nutritional support across both production and companion animal populations. These solutions are pivotal in stabilizing critical care patients, aiding in post-operative recovery, and managing infectious or metabolic diseases, thereby driving their increasing adoption across veterinary hospitals, mobile clinics, and research institutions.
The market is being propelled by multiple converging factors, including the rising prevalence of chronic conditions such as kidney disease, parvovirus, and electrolyte imbalance in pets, along with the rapid intensification of livestock farming that often exposes animals to environmental and nutritional stress. Advances in veterinary diagnostics have enabled early detection of dehydration and systemic infections, thereby necessitating timely intravenous interventions. Moreover, the global push toward enhancing animal welfare, especially in developed markets, has encouraged pet owners and producers alike to invest in quality veterinary care—driving the demand for sterile, customizable IV fluid formulations.
The technological evolution of IV solutions—such as electrolyte-balanced fluids, dextrose infusions, and amino acid-enriched therapies—combined with portable IV delivery devices, is broadening the clinical applications and usability across diverse animal species and field settings. Leading players are also focusing on producing species-specific formulations that reduce adverse reactions and enhance absorption rates. Furthermore, growing awareness of zoonotic risk mitigation and increasing collaborations between veterinary pharmaceutical firms and livestock producers have strengthened supply chain efficiency, making these lifesaving fluids more accessible in remote and rural areas.
Regionally, North America leads the global market, supported by well-established veterinary infrastructure, high pet ownership rates, and comprehensive pet insurance coverage. Europe maintains a strong position with robust veterinary guidelines and animal welfare legislation. However, the Asia Pacific region is anticipated to register the fastest growth over the forecast horizon. Factors such as growing disposable income, rising investments in animal healthcare, and a burgeoning livestock sector in countries like India, China, and Indonesia are playing pivotal roles in the region’s expansion. Meanwhile, Latin America and the Middle East & Africa are expected to gradually gain momentum through increased government-led animal health initiatives and awareness campaigns on sustainable livestock management.
Major market player included in this report are:
• Zoetis Inc.
• Dechra Pharmaceuticals PLC
• Vetoquinol S.A.
• B. Braun Melsungen AG
• Norbrook Laboratories
• ICU Medical, Inc.
• Bayer Animal Health
• Virbac
• Henry Schein, Inc.
• Bimeda Inc.
• Orion Corporation
• Neogen Corporation
• Elanco Animal Health Incorporated
• Fresenius Kabi AG
• Ceva Santé Animale
The detailed segments and sub-segment of the market are explained below:
By Product
• Crystalloids
• Colloids
• Additive Solutions
By Animal Type
• Companion Animals
• Production Animals
By Indication
• Dehydration
• Electrolyte Imbalance
• Nutritional Deficiencies
• Drug Delivery
• Others
By End-use
• Veterinary Hospitals & Clinics
• Homecare Settings
• Research & Academic Institutes
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of MEA
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global Veterinary Intravenous (IV) Solutions Market Executive Summary
1.1. Global Veterinary Intravenous (IV) Solutions Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Animal Type
1.3.3. By Indication
1.3.4. By End-use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Veterinary Intravenous (IV) Solutions Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Buyer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Stakeholder Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Veterinary Intravenous (IV) Solutions Market Dynamics
3.1. Market Drivers
3.1.1. Rising Prevalence of Dehydration and Electrolyte Imbalances
3.1.2. Intensification of Livestock Farming and Nutritional Stress
3.1.3. Advances in Veterinary Diagnostics Enabling Early Intervention
3.2. Market Challenges
3.2.1. Complexity of Customizable Formulations and Cold-Chain Logistics
3.2.2. High Regulatory and Sterility Compliance Costs
3.3. Market Opportunities
3.3.1. Development of Species-Specific and Field-Deployable IV Kits
3.3.2. Bundled Therapeutic and Nutritional IV Solutions
3.3.3. Expansion into Emerging Rural and Mobile Veterinary Services
Chapter 4. Global Veterinary Intravenous (IV) Solutions Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Porter’s Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Veterinary Intravenous (IV) Solutions Market Size & Forecasts by Product 2022–2032
5.1. Segment Dashboard
5.2. Global Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Crystalloids
5.2.2. Colloids
5.2.3. Additive Solutions
Chapter 6. Global Veterinary Intravenous (IV) Solutions Market Size & Forecasts by Animal Type 2022–2032
6.1. Segment Dashboard
6.2. Global Market: Animal Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Companion Animals
6.2.2. Production Animals
Chapter 7. Global Veterinary Intravenous (IV) Solutions Market Size & Forecasts by Indication 2022–2032
7.1. Segment Dashboard
7.2. Global Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Dehydration
7.2.2. Electrolyte Imbalance
7.2.3. Nutritional Deficiencies
7.2.4. Drug Delivery
7.2.5. Others
Chapter 8. Global Veterinary Intravenous (IV) Solutions Market Size & Forecasts by End-use 2022–2032
8.1. Segment Dashboard
8.2. Global Market: End-use Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.2.1. Veterinary Hospitals & Clinics
8.2.2. Homecare Settings
8.2.3. Research & Academic Institutes
Chapter 9. Global Veterinary Intravenous (IV) Solutions Market Size & Forecasts by Region 2022–2032
9.1. North America
9.1.1. U.S. Market
9.1.1.1. Segment breakdown size & forecasts, 2022–2032
9.1.2. Canada Market
9.2. Europe
9.2.1. UK Market
9.2.2. Germany Market
9.2.3. France Market
9.2.4. Spain Market
9.2.5. Italy Market
9.2.6. Rest of Europe Market
9.3. Asia Pacific
9.3.1. China Market
9.3.2. India Market
9.3.3. Japan Market
9.3.4. Australia Market
9.3.5. South Korea Market
9.3.6. Rest of Asia Pacific Market
9.4. Latin America
9.4.1. Brazil Market
9.4.2. Mexico Market
9.5. Middle East & Africa
9.5.1. Saudi Arabia Market
9.5.2. South Africa Market
9.5.3. Rest of MEA Market
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Zoetis Inc.
10.1.2. Dechra Pharmaceuticals PLC
10.1.3. Vetoquinol S.A.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Zoetis Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Dechra Pharmaceuticals PLC
10.3.3. Vetoquinol S.A.
10.3.4. B. Braun Melsungen AG
10.3.5. Norbrook Laboratories
10.3.6. ICU Medical, Inc.
10.3.7. Bayer Animal Health
10.3.8. Virbac
10.3.9. Henry Schein, Inc.
10.3.10. Bimeda Inc.
10.3.11. Orion Corporation
10.3.12. Neogen Corporation
10.3.13. Elanco Animal Health Incorporated
10.3.14. Fresenius Kabi AG
10.3.15. Ceva Santé Animale
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes